Drug Profile

ATI 1701

Alternative Names: ATI-1701

Latest Information Update: 10 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator National Research Council Canada
Developer Appili Therapeutics; National Research Council Canada
Class Anti-infectives; Attenuated vaccines; Bacterial vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Tularaemia

Most Recent Events

10 Apr 2026 Appili Therapeutics plans a phase I trial for Tularaemia (Prevention) in 2025 (Appili Therapeutics, April 2026)
10 Apr 2026 Appili Therapeutics plans a phase II trial for Tularaemia (Prevention) in 2026 (Appili Therapeutics, April 2026)
30 Mar 2026 ATI 1701 is still in preclinical trials for Tularaemia (Prevention) in Canada (Appili Therapeutics Pipeline, April 2026)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com